Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Drug: Lenvatinib, sintilimab plus SIRT
- Registration Number
- NCT05992584
- Lead Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Brief Summary
This study is conducted to evaluate the efficacy and safety of lenvatinib, sintilimab plus Y-90 selective internal radiation therapy (SIRT) for patients with unresectable intermediate-advanced hepatocellular carcinoma (HCC).
- Detailed Description
This is a single-center, prospective study to evaluate the efficacy and safety of lenvatinib, sintilimab plus SIRT (Len-Sin-SIRT) in patient with unresectable HCC.
30 patients with unresectable intermediate-advanced HCC (BCLC B/C stage) will be enrolled in this study. The patients will receive lenvatinib (body weight ≥60kg, 12mg; body weight \<60kg, 8mg; P.O. QD) and sintilimab (200mg I.V. Q3W) at 3-7 days after SIRT. Sintilimab will last up to 24 months, or until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first. Lenvatinib will last until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first.
The primary end point of this study is Progression free survival (PFS) per mRECIST. The secondary endpoints are PFS per RECIST 1.1, objective response rate (ORR), disease control rate (DCR), overall survival (OS) and adverse events (AEs).
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 30
- Unresectable HCC (BCLC stage B/C) with diagnosis confirmed by histology/cytology or clinically
- At least one measurable untreated lesion
- Intrahepatic tumors can be treated with 1-2 session of SIRT
- Child-Pugh score 5-7
- Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1
- Life expectancy of at least 3 months
- Patients with active hepatitis B are allowed, but they need to receive antiviral treatment to achieve a HBV DNA<10^3 IU/mL
- Patients with hepatitis C need to finish the anti-HCV treatment
- tumor extent ≥70% liver occupation
- Tumor thrombus involving main portal vein or both the first left and right branch of portal vein
- Vena cava invasion
- Central nervous system metastasis
- Metastatic disease that involves major airways or blood vessels
- Patients who previously received hepatic arterial infusion chemotherapy (HAIC), transarterial chemoembolization (TACE), transarterial embolization (TAE), radiotherapy, systemic therapy, or immunotherapy for HCC
- History of organ and cell transplantation
- Prior esophageal and/or gastric varices bleeding
- History of hepatic encephalopathy
- Peripheral blood white blood cell count<3×10^9/L, platelet count<50×10^9/L
- Prolongation of prothrombin time ≥ 4 seconds
- Severe organ dysfunction (heart, lungs, kidneys)
- History of malignancy other than HCC
- HBsAg and anti-HCV antibody positive concurrently
- Human immunodeficiency virus (HIV) infected
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Len-Sin-SIRT Lenvatinib, sintilimab plus SIRT Lenvatinib, sintilimab plus SIRT
- Primary Outcome Measures
Name Time Method Progression free survival (PFS) according to mRECIST 2.5 years The time from initiation of treatment until the first occurrence of disease progression or death from any cause, whichever occurs first.
- Secondary Outcome Measures
Name Time Method Adverse Events (AEs) 2.5 years Number of patients with AEs assessed by NCI CTCAE v5.0.
Progression free survival (PFS) according to RECIST 1.1 2.5 years The time from initiation of treatment until the first occurrence of disease progression or death from any cause, whichever occurs first.
Objective response rate (ORR) 2.5 years The percentage of patients who had a best overall tumor response rating of complete response (CR) or partial response (PR) according to mRECIST and RECIST 1.1
Disease control rate (DCR) 2.5 years The percentage of patients who had a tumor response rating of CR, PR, or stable disease (SD) according to mRECIST and RECIST 1.1
Overall survival (OS) 2.5 years The time from initiation of treatment until the date of death from any cause.
Trial Locations
- Locations (1)
The Second Affiliated Hospital of Guangzhou Medical University
🇨🇳Guangzhou, Guangdong, China